Themis Medicare Reports Mixed Financial Results Amidst Declining Profitability in December 2024

Themis Medicare, a small-cap player in the Pharmaceuticals & Drugs industry, recently announced its financial results for the quarter ending December 2024. The evaluation changes reflect a notable shift in the company's financial standing, with the score experiencing a significant adjustment.
The financial data reveals that Themis Medicare has achieved its lowest Debt-Equity Ratio in the last five half-yearly periods, recorded at 0.20 times, indicating a reduction in borrowing relative to equity capital. However, several metrics indicate challenges for the company. Profit Before Tax less Other Income (PBT) has shown a substantial decline, reaching Rs 0.64 crore, which is markedly lower than the average of Rs 15.59 crore from the previous four quarters. Similarly, Profit After Tax (PAT) has also decreased significantly, landing at Rs 0.52 crore compared to an average of Rs 13.25 crore.

Net Sales have followed a downward trajectory, reported at Rs 93.81 crore, down from an average of Rs 105.08 crore. Additionally, the company has recorded its highest interest expense in the last five quarters at Rs 2.79 crore, suggesting increased borrowing costs. The decline in Earnings per Share (EPS) to Rs 0.06 further underscores the challenges in profitability, while cash and cash equivalents have reached their lowest point in six half-yearly periods at Rs 17.60 crore, indicating deteriorating short-term liquidity.

Overall, Themis Medicare's recent financial results highlight a complex landscape of both positive and negative trends.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.